GSK Sales Get Boost From Specialty Medicines
By Adria Calatayud
GSK reported an increase in third-quarter sales, boosted by its specialty medicines segment, as the U.K. drugmaker works to cut costs and speed up the development of its drug pipeline.
The company said Wednesday that third-quarter turnover was 8.89 billion pounds ($11.83 billion), up 4% compared with the year-earlier period. When excluding the effect of currency changes, turnover was 5%. Analysts had forecast GSK's quarterly turnover at 8.84 billion pounds, according to consensus estimates provided by the company.
A jump in sales of specialty medicines allowed GSK to offset a declining vaccines revenue and a flat performance in its general medicines segment.
Pretax profit for the quarter was 1.94 billion pounds compared with 2.46 billon pounds a year before. Net profit dropped to 1.54 billion pounds from 2.01 billion pounds.
Excluding exceptional items and currency effects, core operating profit climbed 5% to 3.08 billion pounds. Analysts had forecast the metric at 2.93 billion pounds, according to the company-compiled consensus.
The company reaffirmed its full-year outlook.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 28, 2026 03:43 ET (07:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States